Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 7/20 | 0.37 |
| ▸ | CSF1R | P07333 | 2/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 2/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | BRS3 | P32247 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2246650 | 0.96 | DAO (0.41) | DAOMAOBCSF1RGPR84CNR2 | |
| Lithium Ion SCHEMBL19630460 | 0.92 | DAO (0.38) | DAOMAOBCSF1RGPR84CNR2 | |
| SCHEMBL14329762 | 0.83 | GPR84 (0.45) | MAOBGPR84MAOA | |
| SCHEMBL13097375 | 0.82 | MAOB (0.53) | DAOMAOBGPR84SLC6A2SLC6A4 | |
| SCHEMBL2253403 | 0.82 | TSHR (0.39) | CSF1RCNR2NAMPTBRS3 | |
| SCHEMBL18030797 | 0.80 | DAO (0.42) | DAOMAOBGPR84MAOA | |
| SCHEMBL2250332 | 0.79 | DAO (0.41) | DAOMAOBGPR84MAOAKDM1A | |
| SCHEMBL15295395 | 0.78 | MAOA (0.50) | MAOBSLC6A2SLC6A4SLC6A3MAOA | |
| SCHEMBL2251358 | 0.78 | TSHR (0.41) | CSF1RCNR2NAMPTBRS3 | |
| SCHEMBL16499616 | 0.78 | DAO (0.45) | DAOMAOBGPR84MAOABRS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180037567-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2018-02-08 | — | — | US | disclosed |
| US-9828361-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2017-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180037567-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP3A4, CYP3A43 | DAO 1470/4885MAOB 296/4885CSF1R 4772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.